Inflammation of the digestive system is brought on by the chronic illness of Inflammatory bowel disease (IBD). White blood cells in the intestines release a protein called fecal calprotectin. It is high in IBD patients, making it a helpful biomarker for identifying and tracking the condition.

Market Dynamics:

The increasing prevalence of gastrointestinal disorders, growing awareness and early detection, and non-invasive and convenient testing are anticipated to drive growth of the global fecal calprotectin test market over the forecast period. Moreover, increasing adoption by healthcare providers is also expected to boost growth of the global fecal calprotectin test market over the forecast period. Emerging markets, point-of-care testing, home-based testing kits, and integration with digital health technology options are expected to create growth opportunities for the global fecal calprotectin test market during the forecast period.

However, limited reimbursement coverage, cost considerations, variability in test results, and limited awareness and physician knowledge are expected to hamper growth of the global fecal calprotectin test market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global fecal calprotectin test market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global fecal calprotectin test market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., ALPCO
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global fecal calprotectin test market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders have ease in decision-making through various strategy matrices used in analyzing the would global fecal calprotectin test market

Detailed Segmentation:

• By Assay Type:
  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Enzyme Fluoroimmunoassay
  • Quantitative Immune-Chromatography
• By Indication:
  • Inflammatory Bowel Disease (IBD) Diagnosis
  • Colorectal Cancer
  • Celiac Disease
  • Others
• By End User:
  • Hospitals
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Others
• By Region:
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East
  • Africa
• Top companies in Fecal Calprotectin Test Market
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Becton, Dickinson and Company
  • Abbexa Limited
  • Bioserv Diagnostics Gmbh
  • Epitope Diagnostics, Inc.
  • LifeSpan BioSciences, Inc.
  • RayBiotech, Inc.
  • ALPCO